WST
West Pharmaceutical ServicesNYSEHealth CareMedical Instruments & SuppliesSnapshot 2026-05-08
As of May 8, 2026, WST has a composite score of 20.8, categorized as "mild favorable." This score is influenced by a medium confidence level of 74.3 and reflects a moderate risk label. Key drivers include macroeconomic factors such as labor, rates, growth, and inflation, with recent guidance changes also impacting the score. The analysis is provisional.
Price
Daily closes from AlphaVantage. Earnings/event dots are placed inline.
Factor signals
Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.
Thesis
— is this a strong company over a 1–3 year hold?Why this rank
- Direction share1.00
- Slope (norm)0.02
- Bonus0.00
Why this rank
Trailing four: 2024-Q3, 2025-Q1, 2025-Q2, 2025-Q3
Why this rank
Watch
— has something changed worth re-reading?Why this setup
EPS estimate $1.99 → $2.08 (+4.6% / 30d). 11 raised, 0 cut, 11 covering analysts.
0 upgrades, 0 downgrades / 30d, 2 maintained. 80% of analysts rate Buy.
2 PT revisions / 30d. Avg target 2.0% above current price.
1 positive, 0 negative / 30d. See F4 management tile for the event list.
Market and fundamentals agree — analysts are positioned bullishly on a fundamentally strong name.
F4 · Management deep-dive — recent events, stated priorities, guidance track record
Recent 8-K events
9 material events in the last 24 months — top 5 listed below.
Stated priorities
3 priorityies extracted from earnings transcripts (as of 2026-05-08).
- 1.Increase full-year 2026 revenue guidancegrowthbehind14% progress
4/23: “Full-year 2026 net sales guidance increased to a range of $3.295 billion to $3.350 billion.”
Why this status
Stated in 2 of last 2 quarters. Full-year 2026 net sales guidance increased from $3.215 billion to $3.350 billion. Revenue for 2025 was $3.074 billion. The trajectory shows progress towards the increased guidance.
- 2.Increase full-year 2026 EPS guidancegrowthbehind14% progress
4/23: “Full-year 2026 adjusted-diluted EPS guidance increased to a range of $8.40 to $8.75.”
Why this status
Stated in 2 of last 2 quarters. Full-year 2026 adjusted-diluted EPS guidance increased from $7.85 to $8.75. EPS for 2025 was $6.79. The trajectory indicates progress towards the increased EPS guidance.
- 3.Introduce Q2 2026 EPS guidancegrowthbehind14% progress
4/23: “The Company is introducing its second-quarter 2026 adjusted-diluted EPS guidance range of $2.05 to $2.12.”
Why this status
Newly stated in 2026-Q1. The Company introduced its second-quarter 2026 adjusted-diluted EPS guidance range of $2.05 to $2.12. This is a new initiative for the quarter, with no prior comparison available.
Guidance track record
Insufficient guidance history for this ticker.
Position context
— how violent might the path be while I hold it?Why this risk level
Recent vol — 30d annualized 42%; 252d 40%.
Drawdown — Max 1y −25%. Bad day move −3%.
Beta to sector ETF (XLV) — 1.03 over 1y.
Liquidity — score 100/100.
Sub-scores — vol 33/100, drawdown 51/100, beta 97/100, earnings vol —.
Calm + bullish setup — clean pre-earnings positioning pattern.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-05-08.
What changed
The most important moves since the prior daily snapshot.
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-05-08
Management scorecard
How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.
Met or beat guidance 100% of the last 1 guided quarters · 11.2% avg surprise
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
- #1
Increase full-year 2026 revenue guidance
GrowthNew since 2026-05-04West Pharmaceutical Services aims to increase its full-year 2026 net sales guidance.
BehindStated in 2 of last 2 quarters. Full-year 2026 net sales guidance increased from $3.215 billion to $3.350 billion. Revenue for 2025 was $3.074 billion. The trajectory shows progress towards the increased guidance.
14%CEO/CFO:“Full-year 2026 net sales guidance increased to a range of $3.295 billion to $3.350 billion.”Press releaseSource dated 2026-04-23Stated 2 of last 8 quartersFirst seen 2026-05-04Show history (2)
- 2026-Q1Press release
“Full-year 2026 net sales guidance increased to a range of $3.295 billion to $3.350 billion.”
- 2025-Q4Press release
“Full-year 2026 net sales are expected to be in a range of $3.215 billion to $3.275 billion.”
- #2
Increase full-year 2026 EPS guidance
GrowthNew since 2026-05-04West Pharmaceutical Services aims to increase its full-year 2026 adjusted-diluted EPS guidance.
BehindStated in 2 of last 2 quarters. Full-year 2026 adjusted-diluted EPS guidance increased from $7.85 to $8.75. EPS for 2025 was $6.79. The trajectory indicates progress towards the increased EPS guidance.
14%CEO/CFO:“Full-year 2026 adjusted-diluted EPS guidance increased to a range of $8.40 to $8.75.”Press releaseSource dated 2026-04-23Stated 2 of last 8 quartersFirst seen 2026-05-04Show history (2)
- 2026-Q1Press release
“Full-year 2026 adjusted-diluted EPS guidance increased to a range of $8.40 to $8.75.”
- 2025-Q4Press release
“Full-year 2026 adjusted-diluted EPS is expected to be in a range of $7.85 to $8.20.”
- #3
Introduce Q2 2026 EPS guidance
GrowthNew since 2026-05-04West Pharmaceutical Services introduced its second-quarter 2026 adjusted-diluted EPS guidance.
BehindNewly stated in 2026-Q1. The Company introduced its second-quarter 2026 adjusted-diluted EPS guidance range of $2.05 to $2.12. This is a new initiative for the quarter, with no prior comparison available.
14%CEO/CFO:“The Company is introducing its second-quarter 2026 adjusted-diluted EPS guidance range of $2.05 to $2.12.”Press releaseSource dated 2026-04-23Stated 1 of last 8 quartersFirst seen 2026-05-04Show history (1)
- 2026-Q1Press release
“The Company is introducing its second-quarter 2026 adjusted-diluted EPS guidance range of $2.05 to $2.12.”
How this stock is priced
Two ways to read price: against peers in the same business, and against the company's own history.
Looks more expensive than peers.
Cheaper than its own typical valuation.
P/E over the last 5 years
62 monthly pointsHow this compares
A side-by-side read on composite, valuation, and risk versus peers.
| Stock | Composite | Valuation | Risk |
|---|---|---|---|
WST West Pharmaceutical Services | +21 | full | moderate |
LLY Lilly (Eli) | +21 | full | moderate |
JNJ Johnson & Johnson | +18 | full | low |
ABBV AbbVie | +12 | fair | low |
UNH UnitedHealth Group | +24 | fair | elevated |
Risk — how this stock moves
What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.
What could change this view
Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.
- If health_care sector trend rises from +0.06 into 'improving' (>= +0.20)+5.0 pts
- If next-quarter guidance is raised (currently NEW as of 2026-04-23)+4.0 pts
- If next-quarter guidance is cut (currently NEW as of 2026-04-23)-8.0 pts
- If labor state reverses from -0.31 (negative) to +0.31 (positive)-6.8 pts
- If health_care sector trend falls from +0.06 into 'weakening' (<= -0.20)-5.0 pts
Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-04-2315d agoItem 2.02
Results of Operations and Financial Condition,” including the exhibit referred to therein, is incorporated herein by reference. A copy of the Company’s presentation materials used during the call will be available through the Investors link at the Company’s website, http://www.westpharma.com, and is also attached hereto as Exhibit 99.2 and incorporated herein by reference. The information in this report (including the exhibits attached hereto) is being furnished pursuant to
earnings preannouncementpositivescore 51 - 2026-03-092mo agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Today, March 9, 2026 , West Pharmaceutical Services, Inc. (the “Company”) announced that Mr. Eric M. Green, President, Chief Executive Officer and Chair of the Board of Directors (the “Board) of the Company, informed the Board on March 6, 2026 of his intent to retire from those positions once his successor has been hired in order to ensure a smooth…
executive changeneutralscore 20 - 2026-02-122mo agoItem 2.02
Results of Operations and Financial Condition,” including the exhibit referred to therein, is incorporated herein by reference. A copy of the Company’s presentation materials used during the call will be available through the Investors link at the Company’s website, http://www.westpharma.com, and is also attached hereto as Exhibit 99.2 and incorporated herein by reference. The information in this report (including the exhibits attached hereto) is being furnished pursuant to
earnings preannouncementpositivescore 10 - 2025-09-117mo agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Today, September 11, 2025, West Pharmaceutical Services, Inc. (the “Company”) announced that Kimberly Banks MacKay, Senior Vice President, General Counsel, and Corporate Secretary, will be leaving the Company. The Company and Ms. MacKay have agreed to discuss an appropriate transition period which will end no later than December 31, 2025, to ensure…
executive changeneutralscore 0 - 2025-07-219mo agoItem 5.01
of a Current Report on Form 8-K as in effect on the date of this Agreement pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, (the “Act”), provided, that, without limitation, a Change in Control shall be deemed to have occurred if: (i) Any Person, other than: (1) the Company, (2) any Person who on the date hereof is a director or officer of the Company, or (3) a trustee or fiduciary holding securities under an employee benefit plan of the Company, is or become…
mna activityneutralscore 0
Score history
The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.